Trial Information

Summary: An open-label dose escalation study of patients with solid tumors treated with STA-9090

This is an open-label Phase 1 dose-escalation study in patients with solid tumors treated with STA-9090 to evaluate for safety, tolerance and efficacy.

This is a dose-escalation study. The first cohort will consist of three patients who will receive 2 mg/m2 of STA 9090 during a 1-hour infusion 2 times per week (e.g., [Monday, Thursday] or [Tuesday, Friday]) for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive 4, 7, 10, 14, 19, 25, 33, 40 and 48 mg/m2 provided that the previous dose was well tolerated during cycle 1 (week 1 – 4). Further dose increments will be approximately 20% over the previous dose level, until the maximum tolerated dose (MTD) is determined.

Major Inclusion Criteria:

• Patients must be documented to be refractory or not candidates for current approved therapies.
• Must have anECOG status 0-2.
• Peripheral neuropathy =2.
• Must have acceptable organ and marrow function per protocol parameters.
• No clinically significant ventricular arrythmias or ischemia.

Major Exclusion Criteria:

• Must not be pregnant or breastfeeding.
• No chemotherapy or radiation within 3 weeks..
• No previous radiation to >25% of total bone marrow.
• No previous high dose chemotherapy with autologous or allogeniec hematopoietic stem cell transplantation.
• No primary brain tumors or active brain metastases.
• No use of any investigational agents within 4 weeks.
• No treatment with chronic immunosuppressants.
• No uncontrolled, intercurrent illness.

Age Limits:

• =25 years of age

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:37:09 AM